Kornimate/medical-research-clean huggingface dataset:
pilot study of text message reminders to improve hiv medication adherence in botswana

Conditions: HIV Infections

Summary: while medication adherence is critical to successful treatment of hiv, there are few studies of interventions demonstrating improvements in adherence. this may be a particular challenge in the developing world, which has a larger burden of hiv but fewer resources than industrialized countries. the investigators propose a randomized controlled trial of cellular phone text message reminders to improve medication adherence. our pilot study will be set in a large hiv clinic in gaborone, botswana, where penn researchers have collaborated on research projects in the past. the primary study outcome will be antiretroviral medication adherence.


Eligibility criteria:
inclusion criteria: * hiv infected * 21 years of age or older exclusion criteria: * subjects who do not intend to have continuous follow-up care and monthly medication refills at independence surgery for at least the next six months

Keywords: hiv antiretrovirals adherence text messaging antiretroviral adherence treatment experienced
mindfulness program for adolescents with 22q11ds

Conditions: 22Q11 Deletion Syndrome

Summary: the goal of this study is to evaluate the effectiveness of the aware program, an online mindfulness education program, with adolescents with 22q11ds and their parents.

parent-adolescent pairs (n=60) will be recruited to participate in a randomized controlled trial. consent, permission, and/or assent will be sought prior to participation in the study. participant pairs will be randomized into one of two study arms: intervention and wait-list control. all participants will complete a web-based pre-test questionnaire. adolescents and parents in the intervention group will then receive access to the aware program for four weeks. approximately 4-5 weeks after completing the pre-test questionnaire, all participants will complete a web-based post-test questionnaire (the post-test for the intervention group will include consumer satisfaction questions about the program). adolescents and parents in the wait-list control group will then have the option of reviewing the aware program and will receive access for four weeks. after approximately four weeks, they will have the opportunity to complete the consumer satisfaction questionnaire about the program.

Eligibility criteria:
inclusion criteria: to be included in the study, youth must: * have received a diagnosis of 22q11.ds (also known as velocardiofacial syndrome or digeorge syndrome) * be between the ages of 12 and 19 years old * have an iq of greater than or equal to 55 * have regular internet and computer access * speak and read english (all study and program materials are in english) to be included in the study, parents must: * have a participating youth in the study * read fluently in english (all study and program materials are in english) exclusion criteria: - only one parent per youth may participate
the treatment of postpartum hemorrhage due to placenta previa complete centralis

Conditions: Placenta Previa Complete Centralis

Summary: objective: to assess the efficacy of lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis. method: this prospective study of 50 women with postpartum hemorrhage following removal of placenta previa complete centralis during elective cesarean section. all 50 patients will have lower uterine compression sutures (involving bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch). all patients will be followed postpartum for evaluation of uterine cavity and menstrual cycles

the investigators conduct a prospective study at department of obstetrics and gynecology, benha university hospital, since june 2012 till july 2014, after approval of the study protocol by the local ethical committee. all patients provide written informed consent to undergo any procedure necessary, including lower uterine compression suturing procedure, as an attempt to avoid hysterectomy. they also provide written informed consent to undergo hysterectomy if all measures attempted to preserve the uterus fail. all patients have placenta previa (50). the inclusion criteria are a gestation age of ≥ 28 weeks and antepartum hemorrhage; intraoperative postpartum hemorrhage and discovery of a placenta accreta; and an adherent placental part after piecemeal removal of the placenta, with bleeding from the placental site, posterior placenta previa and/or successful piecemeal removal of the placenta. the first author performed all cesarean deliveries and assisted by the second author. we open the parietal peritoneum by sharp dissection and blunt expansion, high above the bladder, a bladder flap is made and the bladder is retracted. a small median transverse hysterotomy incision is done in the lower uterine segment. it is expanded on both sides using scissors, stopping shortly before the uterine arteries. active delivery of the placenta is attempted by searching manually for a plane of cleavage between the placenta and the uterus after delivery of the fetus. the study technique comprise lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch).

Eligibility criteria:
inclusion criteria: * a gestation age of ≥ 28 weeks and antepartum hemorrhage; * intraoperative postpartum hemorrhage and discovery of a placenta previa; * successful removal of the placenta exclusion criteria: * shock due to massive blood loss * failure of successful removal of the placenta

Keywords: postpartum hemorrhage placenta previa uterine cavity
prevention of acute kidney injury in patients with nstemi

Conditions: Non-ST Elevation Myocardial Infarction (NSTEMI)

Summary: a randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with nstemi undergoing urgent coronary angiography. approximately 220 patients with ckd and acute nstemi, who are scheduled for an urgent coronary angiography (within 72 hours after admission and/or diagnosis of nstemi).

approximately 220 patients with chronic kidney disease (ckd) and acute nstemi, who are scheduled for an urgent coronary angiography (within 72 hours after admission and/or diagnosis of nstemi) will be screened for the study. only patients with acute nstemi presumed to be a spontaneous myocardial infarction, related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection (i.e. type 1) are eligible. written informed consent will be obtained before urgent coronary angiography. patients with nstemi will typically undergo coronary angiography within 72 hours after admission and/or diagnosis of nstemi. it is estimated that 70% of these patients will have pci. randomization will continue until the 160th patient has had a pci.

Eligibility criteria:
inclusion criteria: 1. informed consent as documented by a signature and date of the patient 2. age 18-85 years 3. acute nstemi as anticipated to be type 1 (expert opinion by the cardiologist before coronary angiography) and scheduled for urgent coronary angiography 4. documented kidney disease existing for ≥3 months or two estimated glomerular filtration rate (egfr) measurements of \<60ml/min/1.73m2 as calculated by the ckd-epi (chronic kidney disease epidemiology collaboration) study equation and at least 6 hours apart or egfr of \<50 ml/min//1.73m2 as calculated by using the ckd-epi study equation at presentation 5. at least one of the following risk factors for aki: diabetes mellitus, age \>60 years, established cardiovascular disease, heart failure with reduced ejection fraction, anemia exclusion criteria: 1. contraindications to the class of drugs under study (c1 esterase inhibitors), e.g. known hypersensitivity or allergy to class of drugs or the imp 2. history or suspicion of allergy to rabbits 3. women who are pregnant or breast feeding 4. st elevation myocardial infarction or unstable angina 5. cardiogenic shock requiring mechanical support 6. non-cardiac comorbidity with expected survival \<6 months 7. acute urinary tract infection (e.g. cystitis, pyelonephritis). 8. liver cirrhosis (any child-pugh score) 9. dialysis or egfr \ 59ml/min/1.73 m2 at baseline (d0) 10. incapacity or inability to provide informed consent 11. participation in another study with investigational drug within 30 days preceding, and during the present study 12. previous enrolment into the current study
bacterial contamination of workwear

Conditions: Bacterial Contamination of Physician Attire

Summary: governmental agencies in the united kingdom and scotland have recently instituted guidelines banning physicians' white coats and wearing of long-sleeved garments to decrease hospital transmission of bacteria. the purpose of this study is to compare the bacterial contamination of physicians' white coats with that of newly laundered, standardized short-sleeved uniforms after an eight-hour workday and to determine the rate at which bacterial contamination of the uniform ensues. our hypothesis was that the physician white coat would have more bacterial contamination at the end of the work day.

governmental agencies in the united kingdom and scotland have recently instituted guidelines banning physicians' white coats and wearing of long-sleeved garments to decrease nosocomial transmission of bacteria. our goal was to compare the degree of bacterial and methicillin-resistant staphylococcus aureus contamination of physicians' white coats with that of newly laundered, standardized short-sleeved uniforms after an eight-hour workday and to determine the rate at which bacterial contamination of the uniform ensues. 100 interns, residents, and hospitalists on an internal medicine service were randomized to wear either physician white coat or newly laundered, short-sleeved uniform. bacterial colony counts and the frequency with which methicillin-resistant staphylococcus aureus was found was compared in the two groups and over time. our initial hypothesis was that physician white coats would have more bacterial contamination at the end of the work day.

Eligibility criteria:
inclusion criteria: * internal medicine interns, residents, and hospitalists working on acute medicine ward service. exclusion criteria: * not willing/unable to participate in study * not working a full 8 hour day in the hospital

Keywords: physician uniform mrsa bacterial contamination
immediate nausea and vomiting after the administration of non-ionic contrast media

Conditions: Contrast Agent; Nausea

Summary: the prevalence of nausea and vomiting after the administration of non-ionic contrast media has rarely been assessed. thus, the aim of our study is to evaluate the prevalence and risk factors of nausea and vomiting after the exposure to the non-ionic contrast media for computed tomography examinations in adults.

there is no robust evidence or guideline for fasting prior to contrast-enhanced ct scan in patients. substantial heterogeneity exists on fasting prior to contrast-enhanced ct worldwide. through dedicated questionnaires, the investigators plan to prospectively assess the prevalence and the risk factors for nausea and vomiting after the exposure to the non-ionic contrast media agent in adult patients undergoing computed tomography examinations.

Eligibility criteria:
inclusion criteria: * patients undergoing contrast-enhanced ct examination with non-ionic contrast media during regular working hours * adult patients (20 years old or older) * patients with informed written consent * patients under observation by medical staffs during and after ct examination up to 30 minutes. exclusion criteria: * patients without informed written consent * age of patients younger than 20 years old * uncooperative patients * pediatric, pregnant, and emergent patients * patients without sufficient observation by medical staffs during and after ct examination up to 30 minutes.

Keywords: nausea vomiting non-ionic contrast media side effect
an observational study to assess the protocol for the covid-19 treatment in burkina faso

Conditions: Coronavirus Infection

Summary: this is an observational study to evaluate the effectiveness of the combinations hydroxychloroquine + azithromycin (hcq-az) and chloroquine + azithromycin (cq-az) in the treatment of coronavirus (covid-19) infection in burkina faso.

all patients who received one of the two combinations will be included in the study and followed-up until the patient is discharged from the hospital. they will be seen daily during the period of their active clinical follow-up at the hospital. at each visit, the medical history since the last visit (including treatments taken), signs and symptoms in progress if any, will be collected. a nasopharyngeal swab will be collected on day 0, 3, 7 and 14 and then on day 21 if he is still positive in order to assess the evolution of the viral load. however if until the end of the follow-up on d21 the test is still positive, the sampling will be continued until the patient become negative as recommended by the national standard of care for the covid patients management in burkina faso. in terms of safety, an ecg will be performed on day 0 prior to the treatment administration and this will be repeated on day 7 and day 14 and every week until it normalizes or the patient will be recommended to see a cardiologist to check the normalization of his ecg after discharge from hospital. adverse events will be recorded including biological parameters (biochemistry and hematology) will be monitored, as well as changes in relevant laboratory parameters.

Eligibility criteria:
inclusion criteria: * any patient over 18 years treated according to the standard of care * willing to participate in the study by giving an informed consent exclusion criteria: * patients under 18 years of age * not willing to participate in the study
a research study, looking at how ryzodeg® (insulin degludec/insulin aspart) works in people with type 2 diabetes in local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how ryzodeg® works in real world patients and to see if ryzodeg® can lower blood sugar levels. participants will get ryzodeg® as prescribed to them by their doctor. the study will last for about 6 to 9 months. participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities. study-related activities are any procedures related to recording of data according to the protocol. * the decision to initiate or switch into treatment with commercially available ryzodeg® has been made by the patient/legally acceptable representative (lar) and the treating physician based on local label before, and independently from, the decision to include the patient in this study. * male or female, age above or equal to 18 years at the time of signing informed consent. * diagnosed with t2dm and treated with any anti-hyperglycaemic medication(s) other than ryzodeg® for at least 26 weeks prior to signing informed consent. * available and documented hba1c value for 12 weeks or less prior to signing informed consent. exclusion criteria: * hypersensitivity to the active substance or to any of the excipients as specified in the ryzodeg® local label. * previous participation in this study. participation is defined as signed informed consent. * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * previous treatment with ryzodeg®.
small/middle tier cities and county lung cancer quality improvement project (qip) study

Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Summary: to evaluate the molecular testing pattern in metastatic nsclc patients after qip; to evaluate the treatment pattern in metastatic nsclc patients after qip.

the primary objective of this study is to assess the implementation of standardized diagnosis and treatment practice in oncology departments of small/middle tier cities and county hospitals, after standardized education and implementation of lung cancer clinical practice guidelines for oncology physicians.

Eligibility criteria:
inclusion criteria: * age ≥18 years, at the time of signing the informed consent. * ecog performance status 0-2. * newly pathologic diagnosed metastatic nsclc (clinical stage iv) or recurrent metastatic nsclc. exclusion criteria: * be participating in other intervention clinical trials. * judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. * previous enrolment in the other qip study.

Keywords: epidermal growth factor receptor nsclc non-small cell lung cancer osbervational
tandospirone citrate in the treatment of patients with generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: the purpose of this study is to evaluate the efficacy and safety of comparative high dose tandospirone citrate in the treatment of patients with generalized anxiety disorder.


Eligibility criteria:
inclusion criteria: * 18-65 years old * male or female * diagnosed with gad according to dsm-iv * hama score≥17 * provide with written informed consent * agree to be washed-out for two weeks if receiving ssri, snri or nasa. exclusion criteria: * serious suicidal tendency * the score of the sixth item of hama ≥3 * the score of hamd ≥21 * pregnant or lactating women * history of allergic or hypersensitivity to tandospirone * serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease * secondary anxiety disorders * drug or alcohol dependence within 1 year * patients currently taking benzodiazepine drugs * drivers and dangerous machine operators * participated in other clinical studies in the last 30 days * patients with clinically significant ecg or laboratory abnormalities * patients with a history of epilepsy * patients with abnormal tsh concentration

Keywords: generalized anxiety disorder
repeated insult patch test of personal lubricants

Conditions: Erythema; Edema

Summary: determine the ability of the study material (personal lubricant) to cause sensitization by repeated topical application to the skin of humans under controlled patch test conditions.


Eligibility criteria:
inclusion criteria: * in general good health * free of any systemic or dermatologic disorder which, in the opinion of the investigative personnel, will interfere with the study results or increase the risk of adverse events * are of any skin type or race, providing the skin pigmentation will allow discernment of erythema * complete a medical screening procedure * read, understand, and sign an informed consent agreement exclusion criteria: * have any visible skin disease at the study site which, in the opinion of the investigative personnel, will interfere with the evaluation * are receiving systemic or topical drugs or medication which, in the opinion of the investigative personnel, will interfere with the study results * have psoriasis and/or active atopic dermatitis/eczema. * are females who are pregnant, planning on getting pregnant during the study, or breast-feeding * have a known sensitivity for cosmetics, skin care products, topical drugs, or any other type of the products, as related to the material being evaluated
icu patient and family comfort study

Conditions: Pain; Thirst; Anxiety; Satisfaction

Summary: the purpose of this study is to evaluate family-led interventions for intensive care unit (icu) patients' symptoms (i.e., pain and thirst) that will involve icu patients' family members in the non-pharmacological management of these symptoms. this family involvement may help to ameliorate not only patients' symptoms but also the families' symptoms and promote family satisfaction with icu care.


Eligibility criteria:
inclusion criteria: * patient: * in icu for at least 24 hours; * adult; * able to self-report; * pain and thirst greater than 3 on 0-10 numeric rating scale; * english-speaking. * family member: * 18 years or older; * visits patient more than other family members; * closest person to patient (can be non-biological). exclusion criteria: * patient: * in icu for at less than 24 hours; * non-adult; * unable to self-report; * no pain and thirst greater than 3 on 0-10 numeric rating scale; * non-english-speaking. * family member: * younger than 18 years; * visits patient less than other family members; * not closest person to patient.
pap therapy in patients with obesity hypoventilation syndrome

Conditions: Obesity Hypoventilation Syndrome

Summary: the role of different levels of compliance and long-term effects of positive airway pressure (pap) therapy on gas exchange, sleepiness, quality of life, depression and death rate in patients with obesity hypoventilation syndrome (ohs).

various forms of positive airway pressure (pap) therapy are effective in providing short and long-term benefits in these patients with or without obstructive sleep apnea (osa). however, there are limited data concerning the impact of long-term effects of pap therapy on survival and functional status in individuals with obesity hypoventilation syndrome (ohs) and osa. therefore we aimed to assess the role of different levels of compliance and long-term effects of pap on gas exchange, sleepiness, quality of life, depression and death rate in patients with ohs, two year after pap initiation.

Eligibility criteria:
inclusion criteria: * aged between 18 and 80 years * obesity hypoventilation syndrome diagnosis (ohs) * clinically stable for at least 4 weeks prior to the enrolment * above-elementary school education. exclusion criteria: * refusal to participate * refusal of pap therapy * central sleep apnea syndromes * restrictive ventilation syndromes * severe congestive heart failure * a history of life-threatening arrhythmias * severe cardiomyopathy * significant chronic kidney disease * untreated hypothyroidism * family or personal history of mental illness * drug or alcohol abuse * sedative use * severe cognitive impairment * concurrent oncological diseases * history of narcolepsy or restless legs syndrome.
women's mammography study to improve comfort during mammography

Conditions: Pain

Summary: to determine in a randomized trial whether it is possible to decrease the discomfort and anxiety of mammography by using the local analgesic lidocaine, or by using calming music in patients receiving a mammogram.

the study is designed to evaluate two methods of reducing pain and anxiety caused by mammography, one of the barriers to the procedure.

Eligibility criteria:
inclusion criteria: * must either be getting her first mammogram or based on prior experience be expecting level 4 or 5 pain. * must have two breasts exclusion criteria: * may not have taken ibuprofen or other pain medication within the space last 12 hours (asa 81 mg dose is allowed). * must not have a contraindication for using lidocaine: e.g no history of allergic reactions to lidocaine. * must not have had history of breast cancer, breast surgery, radiation to the chest wall. * must not have broken or irritated skin (as determined by the study nurses). * may not be lactating or breast feeding

Keywords: mammogram pain management lidocaine